Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zealand Pharma
Biotech
Zealand pumps brakes on development of dual GLP-1/GLP-2 agonist
After dropping so-so results on its dual GLP-1/GLP-2, fierce competition in obesity has persuaded Zealand to aim its development engine elsewhere.
Fraiser Kansteiner
Nov 13, 2025 9:52am
What’s next for Roche’s expensive obesity pipeline?
Sep 19, 2025 10:16am
'Several concerning observations': FDA sheds light on rejections
Sep 5, 2025 10:45am
Zealand's dual agonist tied to 11% weight loss in phase 1b
Jun 18, 2025 3:00pm
Weight of market pressures pushes Novo CEO out—Chutes & Ladders
May 23, 2025 8:30am
Galapagos CEO eyes exit as spinout names leader—Chutes & Ladders
Apr 25, 2025 8:30am
